Evoke Pharma
EVOK
EVOK was delisted on the 16th of December, 2025.
19 hedge funds and large institutions have $6.17M invested in Evoke Pharma in 2021 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 9 closing their positions.
3,821% more call options, than puts
Call options by funds: $745K | Put options by funds: $19K
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
0% more ownership
Funds ownership: 0.09% → 0.1% (+0%)
21% less capital invested
Capital invested by funds: $7.83M → $6.17M (-$1.66M)
24% less funds holding
Funds holding: 25 → 19 (-6)
67% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$399K |
| 2 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$177K |
| 3 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$91K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$70.4K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$58.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$210K |
| 2 |
Creative Planning
Overland Park,
Kansas
|
-$183K |
| 3 |
California Public Employees Retirement System
Sacramento,
California
|
-$67K |
| 4 |
Jane Street
New York
|
-$33K |
| 5 |
UCFA
United Capital Financial Advisors
Irving,
Texas
|
-$26K |
EVOK Hedge Fund Activity: Q2 2021 in Review
19 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q2 2021, worth a combined $6.17M — down 21% from $7.83M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of EVOK and 3 opened new positions — a net loss of 6 holders — while 3 trimmed existing stakes and 5 added.
The largest buyer was AIGH Capital Management, adding an estimated $399K. The largest seller was Morgan Stanley, cutting an estimated $210K.
- 19 institutional investors held Evoke Pharma (EVOK) as of Q2 2021, down from 25 in Q1 2021.
- Funds reported $6.17M of Evoke Pharma stock for Q2 2021, down 21% quarter-over-quarter.
- 3 funds opened new Evoke Pharma positions in Q2 2021 and 9 closed out, a net change of -6 holders.
- The largest Evoke Pharma buyer in Q2 2021 was AIGH Capital Management, an estimated $399K added.
- The largest Evoke Pharma seller in Q2 2021 was Morgan Stanley, an estimated $210K sold.
Based on aggregated 13F filings for Q2 2021.